SCHEMBL1809182

SCHEMBL1809182

O=C(CSc1ccc(-c2cccc([N+](=O)[O-])c2)s1)NCC1CN(Cc2ccc(Cl)c(Cl)c2)CCO1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 3/20 0.46
ALDH1A1 P00352 5/20 0.45
DRD4 P21917 4/20 0.39
RXFP1 Q9HBX9 1/20 0.39
CCR2 P41597 1/20 0.38
UTS2R Q9UKP6 1/20 0.38
CCR1 P32246 2/20 0.38
HPGD P15428 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1809183 1.00 CCR3 (0.46) CCR3ALDH1A1DRD4RXFP1CCR2
SCHEMBL1809669 0.88 CCR3 (0.50) CCR3ALDH1A1DRD4CCR1HPGD
SCHEMBL1809673 0.88 CCR3 (0.50) CCR3ALDH1A1DRD4CCR1HPGD
SCHEMBL1809577 0.88 CCR3 (0.49) CCR3ALDH1A1DRD4CCR1HPGD
SCHEMBL1809572 0.88 CCR3 (0.49) CCR3ALDH1A1DRD4CCR1HPGD
SCHEMBL1807896 0.86 ALDH1A1 (0.47) CCR3ALDH1A1DRD4UTS2RCCR1
SCHEMBL1807892 0.86 ALDH1A1 (0.47) CCR3ALDH1A1DRD4UTS2RCCR1
SCHEMBL1811251 0.86 ALDH1A1 (0.51) CCR3ALDH1A1DRD4RXFP1CCR1
SCHEMBL1811250 0.86 ALDH1A1 (0.51) CCR3ALDH1A1DRD4RXFP1CCR1
SCHEMBL1810840 0.85 CCR3 (0.53) CCR3ALDH1A1DRD4CCR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 CCR3 1/4885ALDH1A1 2661/4885DRD4 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.